Current concepts in venous thromboembolism and major lower limb orthopaedic surgery

International Journal of Clinical Practice

Volumn 56, Issue 4, 2002, Pages 292-297

  McCahill, J P ^a   Carrington, R W J ^a   Skinner, J A ^a  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

AGING; BLEEDING; COMPRESSION THERAPY; CONTROLLED STUDY; HIP FRACTURE; HUMAN; JOINT DEGENERATION; LEG; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL TECHNIQUE; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT; ASPIRIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIP FRACTURES; HUMANS; META-ANALYSIS; PULMONARY EMBOLISM; THROMBOEMBOLISM;

EID: 0036285002     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. United they stand: Co-ordinating care for elderly patients with hip fracture
2. United they stand: Co-ordinating care for elderly patients with hip fracture
3. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement
4. 'Delayed' prophylactic anticoagulation: A study of results and complications in 2012 total hip arthroplasties
5. 2012 total hip arthroplasties: A study of postoperative course and early complications
6. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: An international multicentre trial
7. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: Reappraisal of results of international multicentre trial
8. Prevention of fatal postoperative pulmonary embolism by dextran 40, low doses of heparin or xantinol nicotinate
9. Prevention of venous thromboembolism in general surgical patients: Results of meta-analysis
10. Reduction thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urologic surgery
11. Death and thromboembolic disease after total hip replacement: A series of 1162 cases with no routine chemical prophylaxis
12. Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases
13. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of prospective studies investigating symptomatic outcomes
14. Differences in mortality after fracture of hip: The East Anglian audit
15. Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery
16. Prevention of venous thromboembolism
17. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin: A double blind comparison of certoparin and unfractionated heparin
18. Randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
19. Prevention of thromboembolism in 190 hip arthroplasties: Comparison of LMW heparin and placebo
20. Prevention of deep vein thrombosis after major knee surgery: A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo
21. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
22. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses
23. Prophylaxis against deep-vein thrombosis in total hip replacement: Comparison of heparin and foot impulse pump
24. Prevention of deep-vein thrombosis after total knee replacement: Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system
25. Prevention of deep vein thrombosis in knee arthroplasty: Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression
26. Comparison of the use of a foot pump with the use of low-molecular- weight heparin for the prevention of deep-vein thrombosis after total hip replacement: A prospective, randomized trial
27. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
28. Prevention of venous thromboembolism. International consensus statement: Guidelines compiled in accordance with the scientific evidence
29. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
30. Instructional course lectures. American Academy of Orthopaedic Surgeons. Common complications of total knee arthroplasty
31. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty
32. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip
33. Prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture
34. Place of aspirin in prophylaxis of venous thromboembolism
35. PEP trial. Pulmonary embolism prevention
36. Are symptomatic endpoints acceptable in venous thromboprophylactic studies?
37. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis?
38. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: Comparison of low-molecular-weight heparin and unfractionated heparin
39. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study: A randomized, controlled trial
40. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty
41. Pulmonary embolism: A late complication after major joint surgery
42. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials
43. Late occurring clinical deep vein thrombosis in joint-operated patients
44. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty
45. Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery
46. Mechanisms of hypercoagulability
47. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison
48. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty
49. Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian arthroplasty register
50. Audit of thromboembolic prophylaxis in hip and knee surgery
51. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Ephesus study
52. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Pentathlon 2000 study
53. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
54. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery